Hiebert Lindsey, Hecht Robert, Soe-Lin Shan, Mohamed Rosmawati, Shabaruddin Fatiha H, Syed Mansor Syed Mukhtar, Dahlui Maznah, Azzeri Amirah, McDonald Scott A
Pharos Global Health Advisors, Boston, MA, USA.
Pharos Global Health Advisors, Boston, MA, USA.
Value Health Reg Issues. 2019 May;18:112-120. doi: 10.1016/j.vhri.2018.12.005. Epub 2019 Mar 25.
In Malaysia, more than 330 000 individuals are estimated to be chronically infected with hepatitis C virus (HCV), but less than 2% have been treated to date.
To estimate the required coverage and costs of a national screening strategy to inform the launch of an HCV elimination program.
We designed an HCV screening strategy based on a "stepwise" approach. This approach relied on targeting of people who inject drugs in the early years, with delayed onset of widespread general population screening. Annual coverage requirements and associated costs were estimated to ensure that the World Health Organization elimination treatment targets were met.
In total, 6 million individuals would have to be screened between 2018 and 2030. Targeting of people who inject drugs in the early years would limit annual screening coverage to less than 1 million individuals from 2018 to 2026. General population screening would have to be launched by 2026. Total costs were estimated at MYR 222 million ($58 million). Proportional to coverage targets, 60% of program costs would fall from 2026 to 2030.
This exercise was one of the first attempts to conduct a detailed analysis of the required screening coverage and costs of a national HCV elimination strategy. These findings suggest that the stepwise approach could delay the onset of general population screening by more than 5 years after the program's launch. This delay would allow additional time to mobilize investments required for a successful general population screening program and also minimize program costs. This strategy prototype could inform the design of effective screening strategies in other countries.
在马来西亚,估计有超过33万人慢性感染丙型肝炎病毒(HCV),但迄今为止接受治疗的人数不到2%。
估计全国筛查策略所需的覆盖率和成本,为启动丙型肝炎病毒消除计划提供依据。
我们基于“逐步推进”的方法设计了一种丙型肝炎病毒筛查策略。该方法在早期阶段以注射毒品者为目标人群,延迟开展广泛的普通人群筛查。估计了年度覆盖率要求和相关成本,以确保实现世界卫生组织的消除治疗目标。
2018年至2030年期间总共需要对600万人进行筛查。在早期阶段以注射毒品者为目标人群,将使2018年至2026年的年度筛查覆盖率限制在100万人以内。普通人群筛查必须在2026年启动。总成本估计为2.22亿马来西亚林吉特(5800万美元)。与覆盖率目标成比例,60%的项目成本将在2026年至2030年期间下降。
本研究是首次对国家丙型肝炎病毒消除策略所需的筛查覆盖率和成本进行详细分析的尝试之一。这些结果表明,逐步推进的方法可能会使普通人群筛查在该计划启动后推迟5年以上。这种延迟将有更多时间来筹集成功开展普通人群筛查计划所需的投资,并使项目成本降至最低。这种策略原型可为其他国家设计有效的筛查策略提供参考。